Figure 1: Overview of the mechanisms of action of the repurposed drugs undergoing clinical trials for the treatment of COVID-19 that will be reviewed in this perspective. Compounds in red represent those that are viral entry inhibitors, compounds in green represent disruptors of cellular viral processing, compounds in blue are modulators of the hyperinflammatory phase of infection and compounds in yellow stimulate host immunomodulatory and anti-viral activity. Abbreviations: ACE2, angiotensin converting enzyme 2; IL-6, interleukin–6; IL-1, interleukin- 1; JAK, janus kinase; RdRp, RNA-dependent RNA polymerases; STAT, signal transducer and activator of transcription proteins; P, phosphate; NF-κB, nuclear factor kappa-light-chain-enhancer of activated B cells; IFN-β, interferon-beta; ISRE, interferon stimulated response element.